Skip to content
Inciteful Med

Understanding Your GPA Diagnosis

Last updated:

Granulomatosis with polyangiitis (GPA), formerly Wegener's granulomatosis, is a rare but manageable autoimmune vasculitis. It causes blood vessel inflammation primarily affecting the ears, nose, throat, lungs, and kidneys. With modern treatments, most patients can achieve long-term remission.

Key Takeaways

  • • GPA is a rare type of ANCA-associated vasculitis that causes inflammation in small- and medium-sized blood vessels.
  • • The disease most commonly affects the ears, nose, throat, lungs, and kidneys, which is known as the classic triad.
  • • GPA was formerly known as Wegener's granulomatosis before the medical community officially changed the name in 2011.
  • • Advances in treatment have transformed GPA from a terminal illness into a manageable chronic condition.
  • • The main goal of modern treatment is to quickly stop the inflammation and maintain long-term remission using targeted medications.

Receiving a diagnosis of Granulomatosis with polyangiitis (GPA) can feel overwhelming, especially because most people have never heard of it. It is natural to feel a sense of shock or isolation when told you have a rare disease [1]. However, the most important thing to know right now is that while GPA is a serious condition, it is no longer the life-threatening mystery it once was. Due to major advances in medical research, GPA has been transformed from a terminal illness into a manageable chronic condition [2][3].

What is GPA?

Granulomatosis with polyangiitis (GPA) is a rare type of vasculitis, which is a general term for inflammation of the blood vessels [4][5]. In GPA, your immune system mistakenly attacks your own small- and medium-sized blood vessels [6][7]. This inflammation can restrict blood flow to vital organs and cause areas of inflammatory tissue called granulomas to form [8][9].

GPA is classified as an ANCA-associated vasculitis (AAV) [9][10]. ANCA stands for anti-neutrophil cytoplasmic antibodies—these are specific proteins in the blood that many GPA patients test positive for, which help doctors confirm the diagnosis and predict how the disease might behave [11][12].

To dive deeper into how this works, see The Biology of GPA.

The Classic Triad

While GPA can affect almost any part of the body, it most commonly follows a “classic triad” of organ involvement [13][14]:

  1. Upper Respiratory Tract (Ear, Nose, and Throat): Persistent sinus pain, frequent nosebleeds, or “crusting” inside the nose [14][15].
  2. Lungs: Persistent cough, shortness of breath, chest pain, or lung nodules [10][5].
  3. Kidneys: Inflammation here is often “silent” but can show up in blood or urine tests [10][16].

For a full list of warning signs, read about Symptoms and Warning Signs of GPA.

Why the Name Changed

You may still see the name Wegener’s granulomatosis in older medical records or online. In 2011, the medical community officially changed the name to Granulomatosis with polyangiitis [17][18]. This change was made for two reasons: to use a name that better describes the disease (inflammation of vessels and granulomas) and to distance the condition from Dr. Friedrich Wegener, whose past association with the Nazi party was deemed incompatible with the values of the medical profession [17][19].

Stabilizing Facts for the Newly Diagnosed

It is common to feel a loss of control after a diagnosis, but these facts can help ground your perspective:

  • It is rare, but you aren’t alone: GPA affects approximately 3 out of every 100,000 people [1][20]. While rare, there are dedicated specialists and patient communities focused entirely on this condition.
  • Treatments have revolutionized outcomes: Before the 1970s, GPA was almost always fatal [21][3]. Today, with modern Standard of Care Treatments, the vast majority of patients achieve remission—a state where the disease is no longer active [22][23][24].
  • A “Manageable Chronic Disease”: Doctors now view GPA similarly to other chronic conditions like diabetes or high blood pressure [2][3]. The goal of your care team is to “turn off” the inflammation quickly and then keep it off using maintenance therapy [23][25].
  • Research is accelerating: More new treatments for GPA have been approved in the last decade than in the previous fifty years, giving patients more options with fewer side effects than ever before [22][26].

In This Guide

Frequently Asked Questions

What is Granulomatosis with polyangiitis (GPA)?
GPA is a rare autoimmune disease and a type of vasculitis. It causes your immune system to mistakenly attack your small- and medium-sized blood vessels, leading to inflammation and the formation of inflammatory tissue called granulomas.
What parts of the body are most affected by GPA?
GPA most frequently affects the upper respiratory tract (ears, nose, and throat), the lungs, and the kidneys. This specific pattern of organ involvement is often referred to by doctors as the classic triad.
Why was the name changed from Wegener's granulomatosis to GPA?
The medical community changed the name to Granulomatosis with polyangiitis in 2011 to use a term that better describes the disease process. The change also distanced the condition from Dr. Friedrich Wegener due to his past association with the Nazi party.
Is Granulomatosis with polyangiitis (GPA) fatal?
While GPA was once considered a terminal illness, modern medical advances have transformed it into a manageable chronic condition. Today, with standard of care treatments, the vast majority of patients are able to achieve remission.
What does an ANCA positive test result mean?
ANCA stands for anti-neutrophil cytoplasmic antibodies, which are specific blood proteins found in many GPA patients. Testing positive for these antibodies, such as PR3 or MPO, helps your doctor confirm the diagnosis and predict how the disease might behave.
How will my doctor monitor my GPA disease activity?
Doctors use tools like the Birmingham Vasculitis Activity Score (BVAS) to track your symptoms over time. They will also regularly check blood and urine tests to monitor for silent inflammation, particularly in your kidneys.

Questions for Your Doctor

  • • What is my specific ANCA status (PR3 or MPO), and how does that affect my risk of a future flare-up?
  • • Do I have signs of kidney involvement, such as protein or blood in my urine?
  • • Which induction treatment (like rituximab or cyclophosphamide) is best for my specific case?
  • • What is my Birmingham Vasculitis Activity Score (BVAS), and how will we track it over time?
  • • Can we use 'steroid-sparing' medications to help reduce my long-term exposure to prednisone?

Questions for You

  • • What symptoms first led me to seek medical care, and have they changed since starting treatment?
  • • How would I describe my daily energy levels and 'brain fog' to my doctor?
  • • Do I have a support system in place to help me manage the emotional stress of a rare disease diagnosis?
  • • Have I noticed any new or worsening symptoms in my nose, ears, or throat lately?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    Epidemiology and genetics of granulomatosis with polyangiitis.

    Banerjee P, Jain A, Kumar U, Senapati S

    Rheumatology international 2021; (41(12)):2069-2089 doi:10.1007/s00296-021-05011-1.

    PMID: 34635927
  2. 2

    ANCA-associated vasculitis.

    Yates M, Watts R

    Clinical medicine (London, England) 2017; (17(1)):60-64 doi:10.7861/clinmedicine.17-1-60.

    PMID: 28148583
  3. 3

    Clinic manifestations in granulomatosis with polyangiitis.

    Greco A, Marinelli C, Fusconi M, et al.

    International journal of immunopathology and pharmacology 2016; (29(2)):151-9 doi:10.1177/0394632015617063.

    PMID: 26684637
  4. 4

    Oral manifestations of anti-neutrophil cytoplasmic antibody-associated vasculitis: an update and narrative review of the literature.

    Alamoudi WA, Sollecito TP, Stoopler ET, France K

    Oral surgery, oral medicine, oral pathology and oral radiology 2023; (135(3)):372-384 doi:10.1016/j.oooo.2022.11.013.

    PMID: 36639252
  5. 5

    An update on dıagnosıs and treatment of ANCA assocıated renal vasculıtıs.

    Turkmen K, Ozer H, Tesar V

    International urology and nephrology 2023; (55(11)):2817-2827 doi:10.1007/s11255-023-03565-6.

    PMID: 37010734
  6. 6

    Granulomatosis With Polyangiitis: A Clinical Case.

    Rodrigues F, Oliveira Sá AI, Mendes M, et al.

    Cureus 2022; (14(12)):e32410 doi:10.7759/cureus.32410.

    PMID: 36636531
  7. 7

    Therapeutic Complement Targeting in ANCA-Associated Vasculitides and Thrombotic Microangiopathy.

    Novikov P, Kozlovskaya N, Moiseev S, et al.

    Biomedicine hub 2016; (1(3)):1-11 doi:10.1159/000453106.

    PMID: 31988889
  8. 8

    [ANCA-Associated Vasculitides].

    Stegert M, Neumann T, Daikeler T

    Therapeutische Umschau. Revue therapeutique 2022; (79(5)):229-237 doi:10.1024/0040-5930/a001355.

    PMID: 35583025
  9. 9

    Granulomatosis With Polyangiitis (Wegener Granulomatosis): Then and Now.

    Churg A, Muller NL

    Archives of pathology & laboratory medicine 2025; (150(1)):37-43 doi:10.5858/arpa.2025-0146-RA.

    PMID: 41429180
  10. 10

    ANCA associated vasculitis (AAV): a review for internists.

    Yaseen K, Mandell BF

    Postgraduate medicine 2023; (135(sup1)):3-13 doi:10.1080/00325481.2022.2102368.

    PMID: 35831990
  11. 11

    [Granulomatosis with polyangiitis and microscopic polyangiitis].

    Klapa S, Arnold S, Lamprecht P

    Laryngo- rhino- otologie 2024; (103(7)):490-499 doi:10.1055/a-2217-4457.

    PMID: 38211619
  12. 12

    Granulomatosis with Polyangiitis: Recurrence or Treatment Consequences?

    Diegues A, Tavares J, Sá D, et al.

    European journal of case reports in internal medicine 2021; (8(4)):002448 doi:10.12890/2021_002448.

    PMID: 33987124
  13. 13

    18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in the Assessment of Occult Involvement in Widespread Granulomatosis with Polyangiitis (Wegener's Granulomatosis).

    Saleh Farghaly HR, Alqarni AO, Nasr HA

    Indian journal of nuclear medicine : IJNM : the official journal of the Society of Nuclear Medicine, India 2019; (34(2)):153-156 doi:10.4103/ijnm.IJNM_151_18.

    PMID: 31040531
  14. 14

    A Runny Nose Leads to a Rare Diagnosis: Chronic Sinusitis as a Sole Manifestation of Limited Granulomatosis With Polyangiitis.

    Qudsiya Z, Viqas Z, Baker DL

    Cureus 2023; (15(5)):e39203 doi:10.7759/cureus.39203.

    PMID: 37337503
  15. 15

    Wegener granulomatosis as possible cause of vertigo: case report and review.

    Goderis J, De Schepper S, Vannieuwenhuyze P, Schmelzer B

    B-ENT 2015; (11(1)):67-72.

    PMID: 26513951
  16. 16

    [ANCA-associated vasculitis].

    Krasselt ML, Holle JU

    Innere Medizin (Heidelberg, Germany) 2022; (63(9)):947-960 doi:10.1007/s00108-022-01386-w.

    PMID: 35925127
  17. 17

    Undisclosed facts in Friedrich Wegener's links with Nazism.

    Arkuszewski P, Cieślak-Arkuszewska A

    Histopathology 2025; (86(3)):317-326 doi:10.1111/his.15296.

    PMID: 39104223
  18. 18

    Granulomatosis with polyangiitis: A case report and brief review of literature.

    Lakhani DA, Balar AB, Adelanwa A, et al.

    Radiology case reports 2021; (16(11)):3445-3450 doi:10.1016/j.radcr.2021.08.028.

    PMID: 34527120
  19. 19

    RITUXIMAB: THE DRUG THAT NEVER FAILS TO SURPRISE!

    Seth AA, Patel S, Gangam MA, Hayat SQ

    The Journal of the Louisiana State Medical Society : official organ of the Louisiana State Medical Society 2015; (167(3)):153.

    PMID: 27159476
  20. 20

    Granulomatosis with Polyangiitis with Myocarditis and Ventricular Tachycardia.

    Hanna RM, Lopez E, Wilson J

    Case reports in medicine 2017; (2017()):6501738 doi:10.1155/2017/6501738.

    PMID: 28912820
  21. 21

    An overlap of granulomatosis with polyangiitis and eosinophilic granulomatosis with polyangiitis.

    Surendran S, Gundappa C, Gandhi A, et al.

    Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia 2017; (28(3)):639-644 doi:10.4103/1319-2442.206450.

    PMID: 28540906
  22. 22

    Expanding the Role of Avacopan Beyond Renal Involvement: Clinical Insights from Two Cases.

    Henriques AR, Oliveira N, Castro P, et al.

    Modern rheumatology case reports 2026; doi:10.1093/mrcr/rxag022.

    PMID: 41800550
  23. 23

    Mapping a path forward: addressing disease burden, pathways and solutions in ANCA-associated vasculitis.

    Hellmich B

    Rheumatology (Oxford, England) 2026; (65(Supplement_1)):i1-i5 doi:10.1093/rheumatology/keaf517.

    PMID: 41051263
  24. 24

    Update on targeted treatments for ANCA-associated vasculitis.

    Puéchal X

    Joint bone spine 2025; (92(1)):105768 doi:10.1016/j.jbspin.2024.105768.

    PMID: 39089473
  25. 25

    Recent Advancements in the Management of Anti-neutrophil Cytoplasmic Antibody-Associated Vasculitis: A Systematic Review.

    Arzoun H, Srinivasan M, Thangaraj SR, et al.

    Cureus 2022; (14(2)):e21814 doi:10.7759/cureus.21814.

    PMID: 35155037
  26. 26

    Superiority of Avacopan and Mepolizumab to Glucocorticoid Tapering in the Treatment of Anti-neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis: A Systematic Review.

    Gattu R, Demory Beckler M, Kesselman MM

    Cureus 2024; (16(8)):e67161 doi:10.7759/cureus.67161.

    PMID: 39295694

This page provides an introductory overview of Granulomatosis with polyangiitis (GPA) for educational purposes. Always consult your rheumatologist or healthcare team for specific medical advice, diagnosis, and treatment planning.

Stay up to date

Get notified when new research about Granulomatosis with polyangiitis is published.

No spam. Unsubscribe anytime.